Business Wire

AEM Launches WMO-Compliant Automated Weather Station to Elevate Global Weather Monitoring

Share

AEM, the essential source for environmental insights, today announced its WMO-compliant AEM Apex Automated Weather Station (AWS). This state-of-the-art solution sets a new benchmark for precision, reliability, and durability, meeting the strict standards of the World Meteorological Organization (WMO).

Designed to address the toughest challenges in weather monitoring, the WMO-compliant AWS offers unparalleled accuracy and performance for a variety of critical applications, from localized climate research to large-scale weather networks.

Key Benefits of the WMO-Compliant AWS

  • Precision Data for Better Decisions: Provides WMO-compliant measurements with strict tolerances to support critical applications.
  • Seamless Global Collaboration: Enables efficient data sharing with regional and global partners, fostering enhanced coordination for monitoring and forecasting.
  • Reliability in Extreme Conditions: Built to deliver continuous, accurate data with minimal maintenance, even in the most demanding environments.
  • Future-Proof Design: A scalable, standards-compliant system that evolves with the changing needs of users.

Advanced Specifications

The AEM Apex AWS incorporates cutting-edge components and technology, including:

  • Wind Monitoring: Ultrasonic sensors with wind direction accuracy of < 2° and wind speed accuracy of ± 0.2 m/s.
  • Rain Measurement: Precision load cell technology with accuracy of ± 0.1 mm or 1% at lower rainfall rates.
  • Solar Monitoring: Secondary standard pyranometer for high-quality solar radiation data.
  • Temperature, Humidity, and Pressure Monitoring: Air temperature accuracy up to ± 0.1 K and barometric pressure accuracy of ± 0.15 hPa.
  • Communication Capabilities: Ser[LOG] data logger with 4G modem, TLS 1.3 security, and versatile communication protocols like Modbus, Ethernet, and SMS.

Serving Diverse Markets Across the Public and Private Sector

The WMO- and ICAO- (International Civil Aviation Organization) compliant AWS serves markets across weather monitoring and forecasting. National Meteorological and Hydrological Services can enhance their national weather networks with precise, reliable solutions. Regional Mesonets and research institutions will improve their local forecasting and climate monitoring capabilities, while private sector organizations in aviation, energy, and utilities can optimize operations, ensure safety, and make data-driven decisions using the most precise weather data available.

AEM’s Commitment to Weather Monitoring Excellence

AEM continues to set the standard in weather and environmental monitoring by offering end-to-end solutions, from network design and installation to software and maintenance. Trusted by government agencies, meteorological services, and communities worldwide, AEM has deployed thousands of systems for severe weather, wildfire, and flood risk management.

The AEM Apex AWS integrates seamlessly with AEM’s Elements® 360, a powerful decision-support application designed to unify and simplify data sharing, enhance response coordination, and ensure the safety of communities worldwide.

To learn more about AEM’s WMO-compliant Automated Weather Station and broader weather monitoring solutions, visit https://aem.eco.

About AEM

AEM is combining global technology leaders to empower communities and organizations to survive and thrive in the face of escalating environmental risks. By deploying intelligent sensing networks, operating a secure and scalable data management infrastructure, and delivering high-value analytics through a suite of end-user applications, AEM serves as the essential source for environmental insights. These technologies enable positive outcomes, helping reduce environmental impact and creating a safer world. For more information, visit https://aem.eco/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250113755485/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye